GTC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE ADVANCED SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Genes to Cells (2005) 10, 409-420. doi:10.1111/j.1365-2443.2005.00847.x
© 2005 Blackwell Publishing or its licensors

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tutulan-Cunita, A. C.
Right arrow Articles by Miyakawa, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tutulan-Cunita, A. C.
Right arrow Articles by Miyakawa, T.

Mutational analysis of the yeast multidrug resistance ABC transporter Pdr5p with altered drug specificity

Andreea Cristina Tutulan-Cunita, Makoto Mikoshi, Masaki Mizunuma, Dai Hirata and Tokichi Miyakawa*

Department of Molecular Biotechnology, Graduate School of Advanced Sciences of Matter, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima 739-8530, Japan

Multidrug resistance ABC transporter Pdr5p of Saccharomyces cerevisiae is particularly important due to its ability to export a wide range of unrelated substrates. To clarify its function, we generated Pdr5p mutants by random mutagenesis and screened for mutants with altered drug specificity in vivo by using 5 drug compounds. Nine point mutations that caused significant changes in drug specificity distributed throughout the length of Pdr5p, namely, in the extracellular, transmembrane or cytoplasmic regions of the transporter. We then investigated their effects upon drug resistance, using 36 chemically related or distinct substrates. From this study, overall geometry of the Pdr5p was suggested to contribute in acquiring the enormous range of drug specificity. Based on their ability to inhibit the growth of the mutant strains, the 36 tested drugs were classified into: drugs to which the mutants responded differently (Group 1), drugs to which all the mutants showed sensitivity (Group 2), and drugs to which all the mutants exhibited resistance (Group 3). The ability of the compounds to be partitioned to the plasma membrane seemed an important factor for recognition by Pdr5p.


Communicated by: Yoshinori Ohsumi

* Correspondence: E-mail: tmiyaka{at}hiroshima-u.ac.jp




This article has been cited by other articles:


Home page
Clin. Microbiol. Rev.Home page
R. D. Cannon, E. Lamping, A. R. Holmes, K. Niimi, P. V. Baret, M. V. Keniya, K. Tanabe, M. Niimi, A. Goffeau, and B. C. Monk
Efflux-Mediated Antifungal Drug Resistance
Clin. Microbiol. Rev., April 1, 2009; 22(2): 291 - 321.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. Ernst, P. Kueppers, C. M. Klein, T. Schwarzmueller, K. Kuchler, and L. Schmitt
A mutation of the H-loop selectively affects rhodamine transport by the yeast multidrug ABC transporter Pdr5
PNAS, April 1, 2008; 105(13): 5069 - 5074.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE ADVANCED SEARCH TABLE OF CONTENTS
Copyright © 2005 by Wiley-Blackwell Publishing.